Gland Pharma Limited Stock Bombay S.E.

Equities

GLAND

INE068V01023

Pharmaceuticals

Delayed Bombay S.E. 05:46:23 2024-04-19 am EDT 5-day change 1st Jan Change
1,763 INR +0.08% Intraday chart for Gland Pharma Limited +0.91% -8.34%
Sales 2024 * 56.56B 677M Sales 2025 * 63.32B 758M Capitalization 291B 3.48B
Net income 2024 * 8.48B 102M Net income 2025 * 11.02B 132M EV / Sales 2024 * 4.65 x
Net cash position 2024 * 27.46B 329M Net cash position 2025 * 31.74B 380M EV / Sales 2025 * 4.09 x
P/E ratio 2024 *
34.2 x
P/E ratio 2025 *
26.3 x
Employees 4,585
Yield 2024 *
0.1%
Yield 2025 *
0.19%
Free-Float 38.38%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.08%
1 week+0.91%
Current month-4.28%
1 month-0.54%
3 months-10.27%
6 months+9.67%
Current year-8.34%
More quotes
1 week
1 711.00
Extreme 1711
1 778.00
1 month
1 693.60
Extreme 1693.6
1 878.90
Current year
1 659.05
Extreme 1659.05
2 195.75
1 year
861.50
Extreme 861.5
2 195.75
3 years
861.50
Extreme 861.5
4 350.00
5 years
861.50
Extreme 861.5
4 350.00
10 years
861.50
Extreme 861.5
4 350.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 99-12-31
Director of Finance/CFO - 19-09-29
Chief Tech/Sci/R&D Officer - 97-12-31
Members of the board TitleAgeSince
Director/Board Member 54 22-03-09
Chief Executive Officer 55 99-12-31
Chairman 69 19-06-09
More insiders
Date Price Change Volume
24-04-19 1,763 +0.08% 3 557
24-04-18 1,762 +0.70% 7,084
24-04-16 1,750 -0.09% 4,308
24-04-15 1,751 +0.22% 8,892
24-04-12 1,747 -2.56% 31,325

Delayed Quote Bombay S.E., April 19, 2024 at 05:46 am EDT

More quotes
Gland Pharma Limited is an India-based generic injectables manufacturer. The Company specializes in sterile injectables, oncology, and ophthalmic, with a specific focus on complex injectables, NCE-1s (New Chemical Entities), First-to-File products, and 505(b)(2) filings. The Company functions primarily on a business-to-business (B2B) model and has a record in pharmaceutical research and development, manufacturing, and marketing of complex injectables. The Company offers a range of delivery systems, including liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags, and drops. It is also in the process of including new delivery systems such as pens and cartridges into its product portfolio. Its key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Its therapeutic products categories include Anti Malarials, Anti-Infectives, Anti-Neoplastics, Gynaecological, Hormones, and others.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
12
Last Close Price
1,764 INR
Average target price
1,856 INR
Spread / Average Target
+5.17%
Consensus